Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program

Erbitux has promising results in colorectal cancer trials. Erbitux has a  future in colorectal cancer. Erbitux has some pending trilas that could explode the drug's popularity. Erbitux may have an advantage over Avastin .

The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

The coverage restrictions placed on the FDA-approved indication have no scientific basis and are incompatible with good clinical practice," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Global Research and Development at Amgen. "We are concerned that inappropriately limiting coverage for ESAs at hemoglobin levels less than 10 g/dL will both increase blood transfusions and severely...

BMS and Imclone have joined efforts to allocate more funds for clinical development of the EGFR inhibitor ERBITUX which have shown efficacy in colorectal cancer and head and neck acncer. EGFR is a potential target in other solid tumors like Lung, pancreas, and liver where Erbitux may play a role in treatment. While waiting the results of these clinical trials many oral targeted therapies like Avastin,...

Erbitux has been very successful in the colorectal cancer and head and neck trials.   The EGFR receptor is prevalent in many malignancies, and represents an obvious direction to expand the use of erbitux in other malignancies - ie lung cancer, esophagus, etc. As more indications for erbtitux are developed, looked for sales and profits to increase for an excellent return on the investmen...

     BMS and Imclone have struck a deal for further development of Erbitux across the board in other malignancies.      It puts together more money for clinical trials to potentially broaden uses for this EGFR (Epidermal Growth Factor Receptor) inhibitor.